4678
N. M. Mishra et al. / Tetrahedron Letters 53 (2012) 4676–4678
M.; Bradbury, A. E.; Nolan, T. G.; Semple, J. E. Bioorg. Med. Chem. Lett. 2002, 12,
water and brine, dried over Na2SO4 and concentrated under reduced pressure.
The crude product was subjected to column chromatography yielding pure 3a
(120 mg, 79%). 1H NMR (300 MHz, CDCl3): d 7.63–7.42 (m, 3H), 7.22–7.10 (m,
1203–1208; (b) South, M. S.; Case, B. L.; Wood, R. S.; Jones, D. E.; Hayes, M. J.;
Girard, T. J.; Lachance, R. M.; Nicholson, N. S.; Clare, M.; Stevens, A. M.;
Stegeman, R. A.; Stallings, W. C.; Kurumbail, R. G.; Parlow, J. J. Bioorg. Med.
Chem. Lett. 2003, 13, 2319–2325; (c) Parlow, J. J.; Case, B. L.; Dice, T. A.; Fenton,
R. L.; Hayes, M. J.; Jones, D. E.; Neumann, W. L.; Wood, R. S.; Lachance, R. M.;
Girard, T. J.; Nicholson, N. S.; Clare, M.; Stegeman, R. A.; Stevens, A. M.;
Stallings, W. C.; Kurumbail, R. G.; South, M. S. J. Med. Chem. 2003, 46, 4050–
4062; (d) Breslin, M. J.; Duggan, M. E.; Halczenko, W.; Fernandez-Metzler, C.;
Hunt, C. A.; Leu, C. T.; Merkle, K. M.; Naylor-Olsen, A. M.; Prueksaritanont, T.;
Stump, G.; Wallace, A.; Rodan, S. B.; Hutchinson, J. H. Bioorg. Med. Chem. Lett.
2003, 13, 1809–1812; (e) Hopkins, C.; Neuenschwander, K.; Scotese, A.;
Jackson, S.; Nieduzak, T.; Pauls, H.; Liang, G.; Sides, K.; Cramer, D.; Cairns, J.;
Maignan, S.; Mathieu, M. Bioorg. Med. Chem. Lett. 2004, 14, 4819–4823.
7. (a) De Borggraeve, W. M.; Rombouts, F. J. R.; Van der Eycken, E. V.; Toppet, S.
M.; Hoornaert, G. J. Tetrahedron Lett. 2001, 42, 5693–5695; (b) De Borggraeve,
W. M.; Verbist, B. M. P.; Rombouts, F. J. R.; Pawar, V. G.; Smets, W. J.; Kamoune,
L.; Alen, J.; Van der Eycken, E. V.; Compernolle, F.; Hoornaert, G. J. Tetrahedron
2004, 60, 11597–11612; (c) Claerhout, S.; Sharma, S.; Sköld, C.; Cavaluzzo, C.;
Sandström, A.; Larhed, M.; Thirumal, M.; Parmar, V. S.; Van der Eycken, E. V.
Tetrahedron 2012, 68, 3019–3029.
8. (a) Alen, J.; Robeyns, K.; De Borggraeve, W. M.; Meervelt, L. V.; Compernolle, F.
Tetrahedron 2008, 64, 8128–8133; (b) Alen, J.; Dobrzan´ ska, L.; De Borggraeve,
W. M.; Compernolle, F. J. Org. Chem. 2007, 72, 1055–1057.
9. (a) Azzam, R.; De Borggraeve, W.; Compernolle, F.; Hoornaert, G. J. Tetrahedron
Lett. 2004, 45, 1885–1888; (b) Azzam, R.; De Borggraeve, W. M.; Compernolle,
F.; Hoornaert, G. J. Tetrahedron 2005, 61, 3953–3962; (c) Kaval, N.; Bisztray, K.;
Dehaen, W.; Kappe, C. O.; Van der Eycken, E. Mol. Divers. 2003, 7, 125–134.
10. Pawar, S. V.; Pawar, V. G.; Dehaen, W.; De Borggraeve, W. M. Org. Lett. 2008, 10,
4473–4476.
2H), 5.02 (s, 1H), 4.28 (q, J = 7.1 Hz, 4H), 2.10 (s, 3H), 1.30 (t, J = 7.1 Hz, 6H); 13
C
NMR (75 MHz, CDCl3): d 166.1, 154.8, 149.3, 136.8, 136.1, 130.2, 129.8, 127.1,
125.5, 62.1, 56.1, 18.2, 14.0; HRMS (EI) for C18H19ClN2O5, calcd 378.0982, found
378.0999.
15. See Supplementary data for details.
16. For relevant transformations involving transition metal-catalyzed arylation of
active methylene compounds followed by retro-Claisen fragmentation, see: (a)
Bruggink, A.; McKillop, A. Tetrahedron 1975, 31, 2607–2619; (b) Zeevaart, J. G.;
Parkinson, C. J.; de Koning, C. B. Tetrahedron Lett. 2004, 45, 4261–4264; (c)
Zeevaart, J. G.; Parkinson, C. J.; de Koning, C. B. Tetrahedron Lett. 2007, 48, 3289–
3293; (d) He, C.; Guo, S.; Huang, L.; Lei, A. J. Am. Chem. Soc. 2010, 132, 8273–
8275; (e) Rout, L.; Regati, S.; Zhao, C.-G. Adv. Synth. Catal. 2011, 353, 3340–
3346.
17. The 5:6 ratio was not significantly affected. On the other hand slight
fluctuations in 5:6 ratio could be observed even for two independent runs
under standard conditions.
18. Representative procedure for the 3-alkylation/retro-Claisen sequence.
Preparation of ethyl 2-(6-chloro-5-methyl-3-oxo-4-phenyl-3,4-dihydropyrazin-2-
yl)acetate (6a): To a suspension of K3PO4 (170 mg, 0.8 mmol) in dry THF (4 mL)
3,5-dichloro-2(1H)-pyrazinone 1a (102 mg, 0.4 mmol) and acetoacetic ester 4
(57 mg, 0.44 mmol) were added. The resulting mixture was stirred for 6 h at
80 °C in a sealed screw cap vial. Upon completion of the reaction the mixture
was diluted with ethyl acetate (50 mL) and concentrated with silica gel (ca. 3 g)
under reduced pressure at 50 °C. The crude [5+6] mixture adsorbed on silica
was again diluted with ethyl acetate (50 mL) and then concentrated to dryness.
This was repeated 5 times. We presume that accomplishment of the retro-
Claisen fragmentation (5?6) occurs during this adsorption process through
the reaction with a silica surface.
11. Mehta, V. P.; Sharma, A. K.; Modha, S. G.; Sharma, S.; Meganathan, T.; Parmar,
V. S.; Van der Eycken, E. J. Org. Chem. 2011, 76, 2920–2925.
12. For some representative examples, see: (a) Thompson, W. J.; Jones, J. H.; Lyle, P.
A.; Thies, J. E. J. Org. Chem. 1988, 53, 2052–2055; (b) Colbon, P. J. J.; Foster, A. C.;
Giles, M. E.; Patel, Z.; Singleton, J. T. J. Heterocycl. Chem. 2008, 45, 1451–1456;
(c) Montalbetti, C. A. G. N.; Coulter, T. S.; Uddin, M. K.; Reignier, S. G.; Magaraci,
F.; Grånäs, C.; Krog-Jensen, C.; Felding, J. Tetrahedron Lett. 2006, 47, 5973–5975;
(d) Morgentin, R.; Jung, F.; Lamorlette, M.; Maudet, M.; Menard, M.; Plé, P.;
Pasquet, G.; Renaud, F. Tetrahedron 2009, 65, 757–764.
13. Qu, G.-R.; Mao, Z.-J.; Niu, H.-Y.; Wang, D.-C.; Xia, C.; Guo, H.-M. Org. Lett. 2009,
11, 1745–1748.
14. Representative procedure for the 3-alkylation of 3,5-dichloro-2(1H)-
pyrazinones with active methylene compounds.
silica
O
surface
R1
N
R1
N
O
Si
O
OH
Si
R6
Cl
O
R6
Cl
O
O
+
+
O
O
O
O
O
N
N
COOEt
COOEt
5
6
Preparation of diethyl 2-(6-chloro-5-methyl-3-oxo-4-phenyl-3,4-dihydropyrazin-
2-yl)malonate (3a): To a suspension of K3PO4 (170 mg, 0.8 mmol) in dry THF
(4 mL) 3,5-dichloro-2(1H)-pyrazinone 1a (102 mg, 0.4 mmol) and diethyl
malonate 2a (70 mg, 0.44 mmol) were added. The resulting mixture was
stirred for 5 h at 80 °C in a sealed screw cap vial. Upon completion of the
reaction the mixture was diluted with ethyl acetate (50 mL), washed with
Finally, pure 6a (81 mg, 66%) was isolated via column chromatography. 1H NMR
(300 MHz, CDCl3): d 7.61–7.44 (m, 3H), 7.22–7.12 (m, 2H), 4.18 (q, J = 7.1, 2H),
3.81 (s, 2H), 2.10 (s, 3H); 1.26 (t, J = 7.1, 3H). 13C NMR (75 MHz, CDCl3): d 169.1,
155.5, 151.0, 137.0, 135.1, 130.2, 129.7, 127.1, 125.3, 61.2, 39.7, 18.1, 14.1;
HRMS (EI) for C15H15ClN2O3, calcd 306.0771, found 306.0772.